We have recently shown that immunotherapy with the potent toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) encapsulated in β-cyclodextrin nanoparticles (CDNP-R848) induces regression of established syngeneic experimental glioma, leading to a sustained anti-tumor response and prolonged survival4. The gene discussed is TLR7; the disease is glioma.